Prelude Therapeutics Incorporated (PRLD)
NASDAQ
Closed
Aug 24, 2026
Day's Range
6.1652 wk Range
0.9810Profile - PRLD - Prelude Therapeutics Incorporated
Profile
Mic Code
XNGS
Sector
Healthcare
Industry
Biotechnology
Employees
79
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies targeting cancer. Its primary function is to advance the understanding of molecular diseases and design precision therapies aimed at challenging hematologic malignancies and solid tumors. The company's research is deeply rooted in understanding the intricate biological pathways driving cancer, which allows them to identify novel targets for drug development. Prelude's pipeline consists of a range of compounds in various phases of development, each tailored to inhibit specific cancer-causing proteins and pathways. Operating predominantly in the biopharmaceutical and healthcare sectors, Prelude Therapeutics impacts both the scientific community and the pharmaceutical industry by contributing to the advancement of targeted cancer therapies. The company plays a significant role in the ongoing evolution of precision medicine, striving to offer more personalized and effective treatment options that can potentially improve outcomes and quality of life for patients battling cancer.
Profile Details
Type
Common Stock
Ceo
Dr. Krishna Vaddi D.V.M., Ph.D.
Address
175 Innovation Boulevard
City
Wilmington
State
DE
Zip
19805
Country
United States
Phone
302 467 1280
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
